Last updated on December 2016

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma


Brief description of study

First in human, open-label, sequential dose escalation and expansion study of oral BAL101553 in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma or high-grade glioma.

Detailed Study Description

This is the first study of the oral formulation of BAL101553. BAL101553 will be administered once daily during each day of a 28-day treatment cycle in capsule form to adults with advanced or recurrent solid tumors or recurrent or progressive glioblastoma or high-grade glioma who have failed standard therapy, or for whom no effective standard therapy is available. The primary goal of the study is to find the highest dose of BAL101553 that can safely be given to humans and to assess what side effects occur. The study will start by treating patients with a low dose. Once it has been shown that this low dose is well tolerated, new patients will be treated at higher dose levels ("dose escalation"). Once the highest, well tolerated dose is identified, additional patients will be treated at that dose (this part is called "dose expansion") to further assess the tolerability and potential anticancer activity of oral BAL101553. The study will also measure pharmacokinetics, pharmacodynamic effects and assess biomarkers.

Clinical Study Identifier: NCT02490800

Contact Investigators or Research Sites near you

Start Over

Jeff Evans, Prof

Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
  Connect »

Rebecca Kristeleit, MD

University College London NHS Foundation Trust
London, United Kingdom
  Connect »

Ruth Plummer, MD

Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care
Newcastle upon Tyne, United Kingdom
  Connect »

Juanita Lopez, MD

Royal Marsden Hospital
Sutton, Surrey, United Kingdom
  Connect »